CagriSema (Cagrilintide + Semaglutide) CagriSema is a co-formulated combination therapy containing 2.4 mg each of Cagrilintide (a long-acting amylin analog) and Semaglutide (a GLP-1 receptor agonist), administered as a single weekly subcutaneous injection
Think of it this way: GLP-1 therapy opens the door to significant fat reduction, but without attention to muscle preservation, some of what walks out that door is tissue the body cannot easily afford to lose
As in the case of larger proteins, peptides can form secondary structures, such as an alpha helix, and they can have a tertiary structure
Take the next step in your performance journey
A number of common medications are associated with weight gain, says Dr
BMC Womens Health 11, 27 (2011)